What is Zacks Research’s Forecast for BHC FY2027 Earnings?

Bausch Health Cos Inc. (NYSE:BHC) – Equities researchers at Zacks Research lifted their FY2027 earnings per share (EPS) estimates for shares of Bausch Health Cos in a research report issued to clients and investors on Tuesday, September 22nd. Zacks Research analyst Team now forecasts that the company will post earnings per share of $3.85 for the year, up from their prior forecast of $3.84. Zacks Research currently has a “Strong-Buy” rating on the stock. The consensus estimate for Bausch Health Cos’ current full-year earnings is $4.35 per share. Zacks Research also issued estimates for Bausch Health Cos’ FY2028 earnings at $3.05 EPS.

Bausch Health Cos (NYSE:BHC) last announced its quarterly earnings results on Wednesday, July 29th. The company reported $1.26 EPS for the quarter, beating the consensus estimate of $0.96 by $0.30. Bausch Health Cos had a negative return on equity of 561.95% and a negative net margin of 10.12%.The business had revenue of $2.83 billion during the quarter, compared to analysts’ expectations of $2.59 billion.

Several other equities research analysts have also issued reports on BHC. Weiss Ratings raised shares of Bausch Health Cos from a “sell (d-)” rating to a “sell (d)” rating in a research note on Friday, July 31st. Wall Street Zen upgraded Bausch Health Cos from a “buy” rating to a “strong-buy” rating in a report on Saturday, August 1st. Finally, Jefferies Financial Group raised Bausch Health Cos to a “hold” rating in a research report on Wednesday, July 22nd. One analyst has rated the stock with a Strong Buy rating, five have issued a Hold rating and one has given a Sell rating to the stock. According to MarketBeat.com, the company has a consensus rating of “Hold” and a consensus price target of $8.00.

Bausch Health Cos Price Performance

Shares of BHC opened at $5.80 on Wednesday. The company has a debt-to-equity ratio of 54.68, a quick ratio of 1.08 and a current ratio of 1.44. The firm has a market cap of $2.17 billion, a PE ratio of -1.96 and a beta of 0.37. Bausch Health Cos has a twelve month low of $4.33 and a twelve month high of $8.00. The firm’s 50 day moving average price is $5.95 and its 200 day moving average price is $5.50.

Insider Activity at Bausch Health Cos

In other news, insider Aimee Lenar sold 36,827 shares of the business’s stock in a transaction on Wednesday, August 19th. The shares were sold at an average price of $7.03, for a total value of $258,893.81. Following the completion of the sale, the insider directly owned 334,853 shares in the company, valued at approximately $2,354,016.59. The trade was a 9.91% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. 20.67% of the stock is currently owned by corporate insiders.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently bought and sold shares of the company. Paulson & CO. Inc. acquired a new stake in shares of Bausch Health Cos in the second quarter valued at about $361,151,000. Royal Bank of Canada boosted its stake in Bausch Health Cos by 24.9% during the 1st quarter. Royal Bank of Canada now owns 11,363,498 shares of the company’s stock valued at $61,362,000 after purchasing an additional 2,262,894 shares during the period. MFN Partners Management LP bought a new stake in Bausch Health Cos during the 2nd quarter valued at approximately $29,580,000. Norges Bank acquired a new stake in Bausch Health Cos in the 4th quarter valued at approximately $25,592,000. Finally, Dimensional Fund Advisors LP grew its holdings in Bausch Health Cos by 10.8% in the 1st quarter. Dimensional Fund Advisors LP now owns 3,604,818 shares of the company’s stock valued at $19,456,000 after buying an additional 350,823 shares during the last quarter. Institutional investors and hedge funds own 78.65% of the company’s stock.

About Bausch Health Cos

Bausch Health Companies Inc is a multinational specialty pharmaceutical company headquartered in Laval, Quebec. The company develops, manufactures and markets prescription medicines, over-the-counter products and medical devices, with a focus on gastroenterology, neurology, dermatology and other specialty therapeutic areas.

Its portfolio includes gastrointestinal treatments such as Xifaxan, Trulance and Relistor, as well as products for conditions affecting the central nervous system and skin.